Laura Galli

Laura Galli

Auto-generated profile, based on publicly available information

Laura Galli

Unit of Infectious Diseases, Università Vita e Salute “San Raffaele”, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in The Lancet Oncology
Verified
Journal Article
Closed access
MRMichele Reni
Michele Reni
SCStefano Cordio
Stefano Cordio
CMCarlo Milandri
Carlo Milandri
PPPaolo Passoni
Paolo Passoni
EBElisa Bonetto
Elisa Bonetto
VCValerio Di Carlo
Valerio Di Carlo

1 March 2000 in Gynecologic Oncology
Verified
Journal Article
Closed access
AMAndrea Mariani
Andrea Mariani
MWMaurice J. Webb
Maurice J. Webb
LGLaura Galli
Laura Galli
KPKarl C. Podratz
Karl C. Podratz

4 April 2006 in AIDS
Verified
Journal Article
Closed access
ACAntonella Castagna
Antonella Castagna
ADAnna Danise
Anna Danise
Stefano MenzoStefano Menzo
Stefano Menzo
LGLaura Galli
Laura Galli
NGNicola Gianotti
Nicola Gianotti
ALAdriano Lazzarin
Adriano Lazzarin
We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus. This 48-week, open-label pilot study randomly assigned HIV-infected patients receiving lamivudine-containing HAART and harbouring the M184V mutation to monotherapy with lamivudine 300 mg once daily (lamivudine group) or the discontinuation of all antiretroviral drugs (TI group). The primary endpoint was the occurrence of immunological or clinical failure; immunological failure was defined as the first report of a CD4 T-cell count less than 350 cells/μl, and clinical failure as the occurrence of a Centers for Disease Control and Prevention grade B or C event. The data were analysed on the basis of the intention-to-treat principle. By week 48, 20 of 29 patients in the TI group (69%; 95% CI 51–83%) and 12 of 29 in the lamivudine group (41%; 95% CI 26–59%) had discontinued the study because of immunological or clinical failure, which was significantly delayed in the lamivudine group (P = 0.018). Only patients in the TI group (6/29, 20.7%) experienced grade 3–4 clinical adverse events at least possibly related to HIV-1 (P = 0.02). The mean decline in CD4 cell percentage, viral rebound and recovery of HIV-1 replication capacity were significantly lower in the lamivudine group. The 24-week virological and immunological response after therapy resumption in patients who prematurely discontinued the study was similar in the two groups. In HIV-1-infected patients harbouring a lamivudine-resistant virus, lamivudine monotherapy may lead to a better immunological and clinical outcome than complete therapy interruption.


1 June 1996 in Cancer Letters
Verified
Journal Article
Closed access
CFClaudio Fortis
Claudio Fortis
MFMarco Foppoli
Marco Foppoli
LGLuca Gianotti
Luca Gianotti
LGLaura Galli
Laura Galli
GCGiovanni Citterio
Giovanni Citterio
MBMarco Braga
Marco Braga

1 March 1996 in Diabetes
Verified
Journal Article
Closed access
PDF file
PPPierMarco Piatti
PierMarco Piatti
LMLycilla D Monti
Lycilla D Monti
MCMorena Conti
Morena Conti
LBLaura Baruffaldi
Laura Baruffaldi
LGLaura Galli
Laura Galli
GPGuido Pozza
Guido Pozza
The purpose of the study was to evaluate fasting endothelin-1 levels in subjects with syndrome X, in subjects with insulinoma, and in normal subjects. The single and synergistic contributions of insulin and triglyceride levels to endothelin-1 release were studied in normal subjects. This was achieved by the evaluation of endothelin-1 levels in response to an insulin bolus combined with a euglycemic clamp (protocol A) and during intralipid (test 1) or saline (test 2) infusions lasting 360 min (protocol B). In protocol B, a euglycemic two-step hyperinsulinemic (25 and 125 mU · kg−1 · h−1) clamp was started at 120 min. Subjects with syndrome × showed significantly higher endothelin-1 levels than normal subjects and subjects with insulinoma (7.22 ± 0.89 vs. 2.61 ± 0.38 and 2.49 ± 0.24 pg/ml, P < 0.01). After an insulin bolus, endothelin-1 levels peaked at 10 min (3.71 ± 0.96 pg/ml). The incremental area of endothelin-1 was significantly higher after insulin than after a saline bolus. In test 1, an acute increase in triglyceride levels significantly enhanced endothelin-1 levels, with were further increased by the synergistic contribution of high insulin and triglyceride levels. In test 2, endothelin-1 release was achieved at high insulin levels but remained significantly lower than in test 1. In conclusion, subjects with syndrome × showed higher endothelin-1 levels than normal subjects and subjects with insulinoma. These levels were reproduced in normal subjects by a simultaneous increase in insulin and triglyceride levels.